Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Elisabetta Patorno, Dr.P.H., M.D.

Co-Author

This page shows the publications co-authored by Elisabetta Patorno and Sebastian Schneeweiss.
Connection Strength

14.852
  1. Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes Obes Metab. 2022 03; 24(3):442-454.
    View in: PubMed
    Score: 0.947
  2. Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments. Endocr Rev. 2021 09 28; 42(5):658-690.
    View in: PubMed
    Score: 0.936
  3. The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care. Endocrinol Diabetes Metab. 2020 Jan; 3(1):e00103.
    View in: PubMed
    Score: 0.824
  4. Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care. Diabetes Obes Metab. 2019 08; 21(8):1824-1836.
    View in: PubMed
    Score: 0.792
  5. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care. Circulation. 2019 06 18; 139(25):2822-2830.
    View in: PubMed
    Score: 0.788
  6. Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records. Diabetes Obes Metab. 2018 04; 20(4):974-984.
    View in: PubMed
    Score: 0.724
  7. Preferential prescribing and utilization trends of diabetes medications among patients with renal impairment: Emerging role of linagliptin and other dipeptidyl peptidase 4 inhibitors. Endocrinol Diabetes Metab. 2018 Jan; 1(1):e00005.
    View in: PubMed
    Score: 0.717
  8. Studies with many covariates and few outcomes: selecting covariates and implementing propensity-score-based confounding adjustments. Epidemiology. 2014 Mar; 25(2):268-78.
    View in: PubMed
    Score: 0.553
  9. Risk of ischemic cerebrovascular and coronary events in adult users of anticonvulsant medications in routine care settings. J Am Heart Assoc. 2013 Jul 30; 2(4):e000208.
    View in: PubMed
    Score: 0.531
  10. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA. 2010 Apr 14; 303(14):1401-9.
    View in: PubMed
    Score: 0.423
  11. Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study. Ann Intern Med. 2022 07; 175(7):927-937.
    View in: PubMed
    Score: 0.245
  12. Evolving channeling in prescribing SGLT-2 inhibitors as first-line treatment for type 2 diabetes. Pharmacoepidemiol Drug Saf. 2022 05; 31(5):566-576.
    View in: PubMed
    Score: 0.239
  13. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Ann Intern Med. 2022 01; 175(1):W4-W5.
    View in: PubMed
    Score: 0.238
  14. Linking the Paul Coverdell National Acute Stroke Program to commercial claims to establish a framework for real-world longitudinal stroke research. Stroke Vasc Neurol. 2022 04; 7(2):114-123.
    View in: PubMed
    Score: 0.236
  15. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Ann Intern Med. 2021 11; 174(11):1528-1541.
    View in: PubMed
    Score: 0.234
  16. Validation of obesity-related diagnosis codes in claims data. Diabetes Obes Metab. 2021 12; 23(12):2623-2631.
    View in: PubMed
    Score: 0.232
  17. Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care. Diabetes Obes Metab. 2021 10; 23(10):2320-2328.
    View in: PubMed
    Score: 0.231
  18. Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes. Clin Gastroenterol Hepatol. 2022 06; 20(6):1382-1393.e19.
    View in: PubMed
    Score: 0.230
  19. Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA. Diabetes Care. 2021 08; 44(8):1774-1782.
    View in: PubMed
    Score: 0.229
  20. Effectiveness of angiotensin-neprilysin inhibitor treatment versus renin-angiotensin system blockade in older adults with heart failure in clinical care. Heart. 2021 09; 107(17):1407-1416.
    View in: PubMed
    Score: 0.229
  21. A novel data mining application to detect safety signals for newly approved medications in routine care of patients with diabetes. Endocrinol Diabetes Metab. 2021 Jul; 4(3):e00237.
    View in: PubMed
    Score: 0.226
  22. Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States. Diabetes Obes Metab. 2021 07; 23(7):1542-1551.
    View in: PubMed
    Score: 0.226
  23. Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA. J Gen Intern Med. 2021 09; 36(9):2601-2607.
    View in: PubMed
    Score: 0.224
  24. Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults. Diabetes Care. 2021 03; 44(3):826-835.
    View in: PubMed
    Score: 0.223
  25. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. Circulation. 2021 03 09; 143(10):1002-1013.
    View in: PubMed
    Score: 0.222
  26. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020 08 25; 370:m2812.
    View in: PubMed
    Score: 0.217
  27. Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes. Diabetes Obes Metab. 2020 04; 22 Suppl 3:45-59.
    View in: PubMed
    Score: 0.211
  28. Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018. Diabetes Care. 2020 04; 43(4):921-924.
    View in: PubMed
    Score: 0.209
  29. Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections. Ann Intern Med. 2019 12 17; 171(12):944-945.
    View in: PubMed
    Score: 0.207
  30. Association of Sodium-Glucose Cotransporter 2 Inhibitor Treatment With Risk of Hospitalization for Fournier Gangrene Among Men. JAMA Intern Med. 2019 Nov 01; 179(11):1587-1590.
    View in: PubMed
    Score: 0.205
  31. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study. Ann Intern Med. 2019 08 20; 171(4):248-256.
    View in: PubMed
    Score: 0.201
  32. Fracture Risk After Initiation of Use of Canagliflozin. Ann Intern Med. 2019 07 02; 171(1):80.
    View in: PubMed
    Score: 0.200
  33. Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride. Diabetes Care. 2019 12; 42(12):2204-2210.
    View in: PubMed
    Score: 0.200
  34. Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study. Ann Intern Med. 2019 02 05; 170(3):155-163.
    View in: PubMed
    Score: 0.193
  35. Development and Preliminary Validation of a Medicare Claims-Based Model to Predict Left Ventricular Ejection Fraction Class in Patients With Heart Failure. Circ Cardiovasc Qual Outcomes. 2018 12; 11(12):e004700.
    View in: PubMed
    Score: 0.192
  36. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2019 02; 21(2):434-438.
    View in: PubMed
    Score: 0.190
  37. Safety and Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists: Pilot Implementation of a Near-Real-Time Monitoring Program in Italy. J Am Heart Assoc. 2018 03 10; 7(6).
    View in: PubMed
    Score: 0.183
  38. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ. 2018 02 06; 360:k119.
    View in: PubMed
    Score: 0.182
  39. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. N Engl J Med. 2017 06 08; 376(23):2300-2302.
    View in: PubMed
    Score: 0.174
  40. Variable Selection for Confounding Adjustment in High-dimensional Covariate Spaces When Analyzing Healthcare Databases. Epidemiology. 2017 03; 28(2):237-248.
    View in: PubMed
    Score: 0.170
  41. Patients' perception about risks and benefits of antithrombotic treatment for the prevention of venous thromboembolism (VTE) after orthopedic surgery: a qualitative study. BMC Musculoskelet Disord. 2015 Oct 26; 16:319.
    View in: PubMed
    Score: 0.155
  42. Initiation patterns of statin therapy among adult patients undergoing intermediate to high-risk non-cardiac surgery. Pharmacoepidemiol Drug Saf. 2016 Jan; 25(1):64-72.
    View in: PubMed
    Score: 0.155
  43. Patterns of ß-blocker initiation in patients undergoing intermediate to high-risk noncardiac surgery. Am Heart J. 2015 Oct; 170(4):812-820.e6.
    View in: PubMed
    Score: 0.152
  44. Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a review. Drug Saf. 2015 Mar; 38(3):295-310.
    View in: PubMed
    Score: 0.148
  45. Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations. Diabetologia. 2014 Nov; 57(11):2237-50.
    View in: PubMed
    Score: 0.144
  46. Comparative safety of anesthetic type for hip fracture surgery in adults: retrospective cohort study. BMJ. 2014 Jun 27; 348:g4022.
    View in: PubMed
    Score: 0.141
  47. Glucagon-Like Peptide 1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: A Multisite Population-Based Cohort Study. Am J Epidemiol. 2022 Jul 23; 191(8):1352-1367.
    View in: PubMed
    Score: 0.062
  48. The modifying effects of adiposity on the cardiovascular safety of sulphonylureas. Diabetes Obes Metab. 2021 11; 23(11):2502-2512.
    View in: PubMed
    Score: 0.058
  49. Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model. Clin Epidemiol. 2020; 12:607-616.
    View in: PubMed
    Score: 0.053
  50. Measuring Frailty in Administrative Claims Data: Comparative Performance of Four Claims-Based Frailty Measures in the U.S. Medicare Data. J Gerontol A Biol Sci Med Sci. 2020 05 22; 75(6):1120-1125.
    View in: PubMed
    Score: 0.053
  51. Data Mining for Adverse Drug Events With a Propensity Score-matched Tree-based Scan Statistic. Epidemiology. 2018 11; 29(6):895-903.
    View in: PubMed
    Score: 0.048
  52. Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome. Pharmacoepidemiol Drug Saf. 2018 Dec; 27(12):1361-1370.
    View in: PubMed
    Score: 0.048
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.